Oncotelic Therapeutics, Inc.
OTLC
$0.03
$0.001.00%
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1,563.93% | 1,737.90% | 7,010.70% | 510.83% | -31.78% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1,556.97% | 1,733.23% | 7,292.38% | 507.67% | -31.68% |
| Operating Income | -1,178.18% | -1,733.23% | -7,292.38% | -507.67% | 31.68% |
| Income Before Tax | 62.07% | -514.69% | 55,385.42% | 66.95% | 175.63% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 62.07% | -514.69% | 38,341.88% | 66.95% | 175.63% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -30.12% | -30.53% | 2.80% | -0.30% | -1.32% |
| Net Income | 39.65% | -634.45% | 41,762.19% | 68.30% | 232.46% |
| EBIT | -1,178.18% | -1,733.23% | -7,292.38% | -507.67% | 31.68% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 28.57% | -600.00% | 37,926.67% | 69.14% | 240.00% |
| Normalized Basic EPS | -380.00% | -675.00% | -244.44% | -1,400.00% | 266.67% |
| EPS Diluted | 33.33% | -600.00% | 37,926.67% | 69.14% | 220.00% |
| Normalized Diluted EPS | -425.00% | -675.00% | -244.44% | -1,400.00% | 233.33% |
| Average Basic Shares Outstanding | 9.57% | 8.93% | 8.33% | 4.70% | 1.67% |
| Average Diluted Shares Outstanding | 3.34% | 8.93% | 8.33% | 4.70% | 12.75% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |